Skip to main navigation
Skip to content
  • Careers
  • Contact
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
    • Partners
  • Analyst Coverage
  • Our Approach
    • ADC Landscape
    • I/O Landscape
  • Portfolio
    • A NOVEL PIPELINE
    • ADCS
    • OUR TARGET CATALOG
  • Investors
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Proxy and Annual Meeting
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
    • Partners
  • Analyst Coverage
  • Our Approach
    • ADC Landscape
    • I/O Landscape
  • Portfolio
    • A NOVEL PIPELINE
    • ADCS
    • OUR TARGET CATALOG
  • Investors
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Proxy and Annual Meeting
  • Careers
  • Contact

News releases

May 30, 2023
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
PDF Version
May 24, 2023
Pyxis Oncology to Acquire Apexigen
PDF Version
May 11, 2023
Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
PDF Version
Mar 31, 2023
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version
Mar 22, 2023
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
PDF Version
Mar 16, 2023
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
PDF Version
Feb 13, 2023
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
PDF Version

321 Harrison Avenue
11th Floor, Suite 1
Boston, MA 02118
(617) 453-3596 | info@pyxisoncology.com

Pyxis Oncology
Twitter > Linkedin-in >
Copyright © 2023 Pyxis Oncology   
|   Privacy Policy